alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                           IBIS TECHNOLOGY CORPORATION
<TABLE>
                                   STATEMENT RE: COMPUTATION OF PER SHARE LOSS

                                                  EXHIBIT 11




                                                 THREE MONTHS ENDED              NINE MONTHS ENDED
                                                    SEPTEMBER 30,                  SEPTEMBER 30,
                                             -------------------------     ---------------------------
                                                1995           1996           1995             1996
                                             -----------    ----------     -----------      ---------- 
<S>                                          <C>            <C>            <C>              <C>
Net loss reported .......................    $(1,309,339)   $ (176,766)    $(3,439,471)     $ (733,178)
                                             ===========    ==========     ===========      ==========

Primary and fully diluted loss per share:
Weighted average common
   shares outstanding ...................      3,488,404     5,171,338       3,395,655       4,568,725
                                             ===========    ==========     ===========      ==========


Net loss per common share ...............    $     (0.38)   $   (0.03)     $     (1.01)     $    (0.16)
                                             ===========    ==========     ===========      ==========

</TABLE>


                                       17
EXHIBIT 32.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of Itec Environmental Group,
Inc. (the "Company") on Form 10-QSB for the period ending June 30, 2003 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Michael E. Hofmann, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. ss.1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act
of 2002, that:

1.   The Report fully complies with the requirements of section 13(a) or 15(d)
     of the Securities Exchange Act of 1934; and

2.   The information contained in the Report fairly presents, in all material
     respects, the financial condition and result of operations of the Company.


/s/ Michael E. Hofmann
----------------------
Michael E. Hofmann
Chief Financial Officer

August 18, 2003
August 1, 2017



### JUDGMENT



## The Fourteenth Court of Appeals

RON POUNDS , Appellant

NO. 14

- 16

- 00263

- CV V.

LIBERTY LLOYD S OF TEXAS INSURANCE C OMPANY , Ap pellee

________________________________ This cause, an appeal from the judgment in favor of appellee, Liberty Lloyd s of Texas Insurance Company, signed February 26, 2016, w as heard on the transcript of the record. We have inspected the record and find no error in the judgment. We order the judgment of the court below AFFIRMED

. We order appell ant, Ron Pounds, to pay all costs incurred in this appeal.

We further order this decision certified below for observance.
IN THE DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FIFTH DISTRICT

NOT FINAL UNTIL TIME EXPIRES TO

FILE MOTION FOR REHEARING AND

DISPOSITION THEREOF IF FILED

JAMES A. GEORGE, JR.,

Petitioner,

v.

Case No. 5D22-1834

LT Case No. 2019-CF-978

STATE OF FLORIDA, 

Respondent. 

________________________________/

Opinion filed October 7, 2022 

Petition for Belated Appeal,

A Case of Original Jurisdiction. 

James A. George, Jr., Raiford, pro se. 

Ashley Moody, Attorney General, 

Tallahassee, and Rebecca Rock 

McGuigan, Assistant Attorney General, 

Daytona Beach, for Respondent. 

PER CURIAM. 

The petition for belated appeal is granted. A copy of this opinion shall 

be filed with the trial court and treated as the notice of appeal from the

December 30, 2019 judgment and sentence rendered in Case No. 2019-
2

CF-978, in the Circuit Court in and for Hernando County, Florida. See Fla. 

R. App. P. 9.141(c)(6)(D).

PETITION GRANTED.

WALLIS, EISNAUGLE, and HARRIS, JJ., concur.
§ 99.301 Agency action on a submission. ( a ) *Submissions.* Within 60 days after receiving a submission under this part, FDA may: ( 1 ) Determine that the manufacturer does not comply with the requirements under this part and that, as a result, the manufacturer shall not disseminate any information under this part;
( 2 ) After providing the manufacturer notice and an opportunity for a meeting, determine that the information submitted regarding a new use fails to provide data, analyses, or other written matter that is objective and balanced and: ( i ) Require the manufacturer to disseminate additional information, including information that the manufacturer has submitted to FDA or, where appropriate, a summary of such information or any other information that can be made publicly available, which, in the agency's opinion: ( A ) Is objective and scientifically sound;
( B ) Pertains to the safety or effectiveness of the new use; and
( C ) Is necessary to provide objectivity and balance; and
( ii ) Require the manufacturer to disseminate an objective statement prepared by FDA that is based on data or other scientifically sound information available to the agency and bears on the safety or effectiveness of the drug or device for the new use; and
( 3 ) Require the manufacturer to maintain records that will identify individual recipients of the information that is to be disseminated when such individual records are warranted due to special safety considerations associated with the new use.
( b ) *Protocols/Studies.* Within 60 days after receiving a submission under this part, FDA shall: ( 1 ) If the manufacturer has planned studies that will be needed for the submission of a supplemental application for the new use, review the manufacturer's proposed protocols and schedule for completing such studies and determine whether the proposed protocols are adequate and whether the proposed schedule for completing the studies is reasonable. FDA shall notify the manufacturer of its determination; or
( 2 ) If the manufacturer has completed studies that the manufacturer believes would be an adequate basis for the submission of a supplemental application for the new use, conduct a review of the protocols submitted for such studies to determine whether they are adequate. FDA shall notify the manufacturer of its determination.
III

103D CONGRESS

2D SESSION S. RES. 188

To recognize the outstanding service of the Architect of the Capitol, the

Honorable George M. White, for the restoration of the Statue of Freedom.

IN THE SENATE OF THE UNITED STATES

MARCH 11 (legislative day, FEBRUARY 22), 1994

Mr. MOYNIHAN (for himself and Mr. WARNER) submitted the following

resolution; which was considered and agreed to

RESOLUTION

To recognize the outstanding service of the Architect of

the Capitol, the Honorable George M. White, for the

restoration of the Statue of Freedom.

Whereas the Statue of Freedom Triumphant in Peace and

War has stood atop the tholos of the United States Capitol Dome since December 2, 1863;

Whereas the Statue of Freedom has served since its installation as an object of great national pride and inspiration;

Whereas the Statue, modeled by the American sculptor

Thomas Crawford in Rome, and cast by Clark Mills in

Northeast Washington, D.C., using bronze made of zinc,

Lake Superior copper, and tin purchased in New York,

was found after inspection in 1988 to be suffering from

rust and corrosion and to be in need of repair;
2

•SRES 188 ATS

Whereas the plan developed by the Architect of the Capitol

for carrying out the necessary repairs required great skill

and expertise in historical restoration techniques as well

as extraordinary feats of engineering for the removal and

replacement of the Statue; and

Whereas Members of Congress, residents of Washington,

D.C., and visitors watched with awe and appreciation as

the Architect’s plan unfolded, accomplishing the removal,

restoration, and replacement of the Statue atop the

Dome in time for the 200th anniversary of the laying of

the cornerstone of the Capitol: Now, therefore, be it

1 Resolved, That the Architect of the Capitol, the Hon2 orable George M. White, is recognized and commended for

3 outstanding service to the Capitol and to the Nation for

4 successfully restoring the original grandeur of the Statue

5 of Freedom.

6 SEC. 2. The Secretary shall transmit a copy of this

7 resolution to the Architect of the Capitol, the Honorable

8 George M. White.

Æ
<PAGE>

                                                                    EXHIBIT 31.2

                                  CERTIFICATION

I, Francis H. Murphy, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Biopure Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement
      of a material fact or omit to state a material fact necessary to make the
      statements made, in light of the circumstances under which such statements
      were made, not misleading with respect to the period covered by this
      report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) for the registrant
      and have:

      (a) Designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures to be designed under our supervision,
      to ensure that material information relating to the registrant, including
      its consolidated subsidiaries, is made known to us by others within those
      entities, particularly during the period in which this report is being
      prepared;

      (b) Evaluated the effectiveness of the registrant's disclosure controls
      and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation; and

      (c) Disclosed in this report any change in the registrant's internal
      control over financial reporting that occurred during the registrant's
      most recent fiscal quarter (the registrant's fourth fiscal quarter in the
      case of an annual report) that has materially affected, or is reasonably
      likely to materially affect, the registrant's internal control over
      financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based
      on our most recent evaluation of internal control over financial
      reporting, to the registrant's auditors and the audit committee of the
      registrant's board of directors (or persons performing the equivalent
      functions):

      (a) All significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which are
      reasonably likely to adversely affect the registrant's ability to record,
      process, summarize and report financial information; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal control
      over financial reporting.

Date: March 14, 2005

/s/ Francis H, Murphy
---------------------
Francis H. Murphy
Chief Financial Officer
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1380 Nuclear flood source phantom. ( a ) *Identification.* A nuclear flood source phantom is a device that consists of a radiolucent container filled with a uniformly distributed solution of a desired radionuclide. It is intended to calibrate a medical gamma camera-collimator system for uniformity of response.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 892.9.
[53 FR 1567, Jan. 20, 1988, as amended at 54 FR 13832, Apr. 5, 1989; 66 FR 38819, July 25, 2001]
## Court of Appeals

Twelfth Court of Appeals District at Tyler



## B I L L O F C O S T S

Court of Appeals No. 12-13-00282-CV

Trial Court No. 11-CV-31,845

Sherilyn Alexander Landers and Billye C. Alexander, Heirs of W. W.

Alexander and Jerrell Fleming, Sharon Fleming, LaVey Alexander and

Dianne Batson

Vs.

Richard Livingston and Dianne Livingston

DOCUMENTS FILED AMOUNT FEE PAID BY

Motion fee

Motion fee

Motion fee

Motion fee

Clerk's record Indigent Filing Supreme Court chapter 51 fee Required Texas.gov efiling fee Filing Reporter's record Indigent Required Texas.gov efiling fee Supreme Court chapter 51 fee $10.00
$10.00
$10.00
$10.00
$396.00
$25.00
$100.00
$50.00
$20.00
$100.00
$190.15
$25.00
$20.00
$50.00 Melissa Ray Phillip Danks Phillip Danks Phillip Danks

Unknown

Bull & Barrett

Bull & Barrett

Bull & Barrett

Bull & Barrett Phillip A. Danks

Jerrell & Sharon Fleming Phillip A. Danks Phillip A. Danks Phillip A. Danks

TOTAL: $1,016.15I, Cathy S. Lusk, Clerk of the Court of Appeals, Twelfth Court of Appeals District at Tyler,

Texas, certify that the above copy of the Bill of Costs is true and correct. GIVEN UNDER MY

HAND AND SEAL OF SAID COURT, at Tyler, this 16th day of March 2015

, A.D.

CATHY LUSK, CLERK

By:

_____________________________ Katrina McClenny, Chief Deputy Clerk
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                             122
<SECURITIES>                                         0
<RECEIVABLES>                                    6,206
<ALLOWANCES>                                       260
<INVENTORY>                                      5,441
<CURRENT-ASSETS>                                12,375
<PP&E>                                           4,499
<DEPRECIATION>                                   3,025
<TOTAL-ASSETS>                                  18,539
<CURRENT-LIABILITIES>                            9,623
<BONDS>                                          1,532
<PREFERRED-MANDATORY>                              810
<PREFERRED>                                          0
<COMMON>                                            56
<OTHER-SE>                                       6,851
<TOTAL-LIABILITY-AND-EQUITY>                    18,539
<SALES>                                         14,311
<TOTAL-REVENUES>                                14,311
<CGS>                                            9,314
<TOTAL-COSTS>                                   16,471
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   485
<INTEREST-EXPENSE>                                 202
<INCOME-PRETAX>                                (1,876)
<INCOME-TAX>                                        13
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,889)
<EPS-BASIC>                                     (0.12)
<EPS-DILUTED>                                   (0.12)


</TABLE>
----

 

**EXHIBIT 31.2**

**CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ike Makrimichalos, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Susglobal Energy Corp. for the fiscal year ended December 31, 2019; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

|   |
|--------|
|   |   |   |   |
| Date:  | May 14, 2020 | By: | /s/ Ike Makrimichalos |
|   |   |   | Ike Makrimichalos |
|   |   |   | Chief Financial Officer (Principal Financial and Accounting Officer) |

----
Exhibit 99.1

CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant
to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Chief Executive Officer of
The Timberland Company (the "Company"), does hereby certify that to the undersigned's knowledge:



| |  | /s/JEFFREY B. SWARTZJeffrey B. Swartz
Chief Executive Officer
| |  | -------------------------------------------------------------

Date: May 12, 2003

A
signed original of this written statement, required by Section 906, has been provided to The Timberland Company and will be retained by The Timberland Company and furnished to the Securities
and Exchange Commission or its staff upon request.

---

QuickLinks
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 00-50199

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

JOSE SANTOS LOZANO-GUTIERREZ, ALSO KNOWN AS Santos Lozano,

also known as Santos Lozano Gutierrez,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Western District of Texas

USDC No. SA-99-CR-453-1-HG

--------------------

December 13, 2000

Before DAVIS, STEWART, and PARKER, Circuit Judges.

PER CURIAM:*

Jose Santos Lozano-Gutierrez pleaded guilty to illegal

reentry into the United States after having been previously

deported. His sentence was enhanced because his prior

deportation occurred following a felony conviction. See 8 U.S.C.

§ 1326(b). For the first time on appeal, Lozano-Gutierrez argues

that, under Apprendi v. New Jersey, 120 S. Ct. 2348, 2362 (2000),

the indictment in his case was deficient because it failed to
No. 00-50199

-2-

allege that his prior deportation followed a conviction for an

aggravated felony under § 1326(b).

Lozano-Gutierrez’s argument is without merit given the

Supreme Court’s decision in United States v. Almendarez-Torres,

523 U.S. 224 (1998). The Court in Apprendi did not overrule its

holding in Almendarez-Torres. See Apprendi, 120 S. Ct. at 2362-

63. Lozano-Gutierrez’s guilty-plea conviction is therefore

AFFIRMED.
**Exhibit 32.01**

 

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**REQUIRED BY RULE 13a-14(b) or RULE 15d-14(b)**

**AND SECTION 906 OF THE SARBANES-OXLEY ACT**

**OF 2002, 18 U.S.C. SECTION 1350**

 

In connection with the Quarterly Report of Williams Controls, Inc (the “Company”) on Form 10-Q for the period ended

March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patrick W. Cavanagh, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

 

|   | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

 

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

 

 

 

/s/ PATRICK W. CAVANAGH

Patrick W. Cavanagh

Chief Executive Officer

Williams Controls, Inc.

May 11, 2010

 

----
<page>   EXHIBIT 32.01

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Dean Witter Principal
Plus Fund L.P. (the ?Partnership?) on Form 10-Q for the period
ended June 30, 2003 as filed with the Securities and Exchange
Commission on the date hereof (the ?Report?), I, Jeffrey A.
Rothman, President, Demeter Management Corporation, general
partner of the Partnership, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:  	/s/Jeffrey A. Rothman

Name:		   Jeffrey A. Rothman
Title:	   President

Date:		   August 14, 2003
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                                        <C>
<PERIOD-TYPE>                                    6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                      22,123,499
<SECURITIES>                                         0
<RECEIVABLES>                                  918,261
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            23,220,105
<PP&E>                                       2,731,895
<DEPRECIATION>                                 757,989
<TOTAL-ASSETS>                              32,641,652
<CURRENT-LIABILITIES>                       20,941,002
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    500,000
<COMMON>                                         5,183
<OTHER-SE>                                  11,170,839
<TOTAL-LIABILITY-AND-EQUITY>                32,641,652
<SALES>                                              0
<TOTAL-REVENUES>                             2,472,285
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                            27,245,775
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             594,901
<INCOME-PRETAX>                           (24,804,509)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (24,804,509)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (24,804,509)
<EPS-PRIMARY>                                   (0.51)
<EPS-DILUTED>                                   (0.51)
        


</TABLE>
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5270 C-reactive protein immunological test system. ( a ) *Identification.* A C-reactive protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the C-reactive protein in serum and other body fluids. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.
( b ) *Classification.* Class II (performance standards).